Multi-Cancer Early Detection Test: What Employers Should Know After the FDA Panel Vote

On September 23, 2026, an FDA advisory panel voted in favor of GRAIL’s Galleri test, putting the first multi-cancer early detection test one step closer to approval. For employers, the vote raises a real question that will land on your desk before the 2028 plan year: should your health plan cover a blood test that screens for dozens of cancers at once? Here is what happened, what the evidence shows, and how to build a clear, fiduciary strategy before the vendor calls start.

What Happened at the FDA Panel on the Galleri Multi-Cancer Early Detection Test

The FDA’s Molecular and Clinical Genetics Panel met to review GRAIL’s premarket approval application for Galleri, a prescription blood test intended for screening adults aged 50 and older for multiple types of cancer. GRAIL filed that application on January 29, 2026, and the test has held Breakthrough Device status since 2018.

The panel’s recommendation on this multi-cancer early detection test is advisory. The FDA is not bound by it and is expected to issue a final decision in the coming months. Still, a favorable vote is a meaningful signal, and it is the first time a multi-cancer early detection test has cleared this stage of federal review.

The Three Votes

According to GRAIL’s announcement of the panel results, ten voting members answered three questions:

Why the Effectiveness Split Matters

Safety was never seriously in doubt. A blood draw carries little physical risk, and no panelist voted against the safety of the multi-cancer early detection test. The effectiveness vote is the one to watch. Four of ten panelists were not persuaded that the current evidence shows the test works well enough, and several yes votes were openly tentative.

Panelists pushed back on the “early detection” label, pressed GRAIL on false positives, and raised the absence of evidence that the test reduces cancer deaths. They also warned that a negative result could give people a false sense of security. That split will shape how carriers, TPAs, and stop loss partners read the eventual approval, and it should shape how you read it too.

How a Multi-Cancer Early Detection Test Works

Most cancer screenings look for one cancer at a time. A mammogram looks for breast cancer. A colonoscopy looks for colorectal cancer. A multi-cancer early detection test takes a different approach: it analyzes a single blood sample for signals that many different cancers can leave behind.

Galleri uses next-generation sequencing to look for cancer-specific methylation patterns in cell-free DNA, the small fragments of genetic material that cells shed into the bloodstream. When the test finds a cancer signal, it also predicts where in the body the signal likely came from, which helps a physician decide what follow-up imaging or testing to order.

A positive multi-cancer early detection test result is a signal, not a diagnosis. Every positive result leads to more workups, such as imaging, specialist visits, and sometimes biopsies. A negative result does not rule out cancer. Both points matter for plan cost and for how you talk to members.

It is easy to see why the idea resonates with employees. Many cancers have no recommended screening at all, and those cancers are often found late, when treatment is harder and more expensive. One blood draw that could catch some of them earlier is a powerful promise. That is exactly why employers need a clear view of what the evidence supports today, and what it does not, before members start asking HR why the plan does not cover it.

What the Clinical Evidence Shows

The panel reviewed data from two large studies in adults over 50, including PATHFINDER 2 in North America and the NHS-Galleri trial in England. The PATHFINDER 2 numbers give employers considering a multi-cancer early detection test the clearest picture of what to expect in a working-age population.

PATHFINDER 2 at a Glance

GRAIL presented PATHFINDER 2 results from 35,878 participants at the 2026 ASCO Annual Meeting. Key findings include:

• Specificity of 99.6%. Fewer than 0.4% of people without cancer received a false positive.
• Positive predictive value of 60.3%. Of 287 people who received a cancer signal, 173 were diagnosed with cancer.
• Sensitivity of 39.3% across all cancers within 12 months, rising to 69.8% for the 12 cancers responsible for about two-thirds of cancer deaths.
• 70.9% of newly detected cancers were found at Stages I to III, when curative treatment is more feasible.
• A median of 48 days to reach a diagnostic resolution after a positive result, with 0.6% of participants needing an invasive procedure.

In plain terms, this multi-cancer early detection test rarely raises a false alarm, and when it does flag something, cancer is confirmed more often than not. The tradeoff is sensitivity. Across all cancers, the test missed more cancers than it caught within a year, and performance is weaker for some common early-stage tumors.

The Questions That Remain Open

The biggest open question is mortality. The National Cancer Institute’s Division of Cancer Prevention states that no definitive clinical trials have yet shown that multi-cancer detection tests reduce overall cancer deaths. NCI is launching its own Vanguard study of roughly 24,000 participants to lay the groundwork for larger trials.

NCI also recommends that standard screenings continue regardless of whether a person takes a multi-cancer test. That includes mammograms, cervical cancer screening, colonoscopies, and lung cancer screening. The FDA panel echoed the same point: this test is an add-on, never a replacement.

For a plan sponsor, that framing is important. Payers will ask first whether screening with a multi-cancer early detection test helps members live longer. Today, the honest answer is that we do not know yet.

The Coverage Path: Medicare, Commercial Plans, and the ACA

FDA approval is the gate every multi-cancer early detection test coverage decision now waits behind. Once that gate opens, Medicare, carriers, and self-funded plans will each move on their own timeline.

Medicare and the MCED Act

The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act became law on February 3, 2026. As the Prevent Cancer Foundation explains, the law creates a Medicare pathway for these tests once they are FDA approved, and it states that coverage of existing screenings should not be affected.

Under the legislation, Medicare coverage can begin as early as 2028, subject to FDA approval and a CMS coverage determination. A National Coverage Determination will set eligibility, frequency, and medical necessity criteria, and commercial carriers often take their cue from it.

Commercial Plans and ACA Preventive Care Rules

Today, the Galleri test lists for $949, and most health plans do not cover it. Members who want the test usually pay out of pocket.

FDA approval of a multi-cancer early detection test alone will not change that for most plans. The ACA requires non-grandfathered plans to cover preventive services without cost sharing when they carry an A or B grade from the U.S. Preventive Services Task Force. Galleri has no USPSTF grade, so the preventive care mandate does not apply, even after approval. That leaves coverage as a plan design choice, and for self-funded employers, it is your choice.

What a Multi-Cancer Early Detection Test Means for Employer Health Plans

Nothing changes for your plan today. But you should expect the question before your 2028 renewal, and you will be in a stronger position if you answer it with a documented strategy rather than a reaction to a sales pitch.

Expect Vendor Outreach Now

GRAIL and point solution partners are likely to reference the panel vote in sales conversations. Keep two facts in front of you. A favorable panel vote is not an approval, and the final FDA label may narrow the claims the test can make. Hold any commitment to cover a multi-cancer early detection test until you see the approved labeling.

Model the Full Cost, Not Just the Test

At $949 per test, screening 100 members aged 50 and older costs roughly $95,000 per year before a single follow-up. Every positive result triggers imaging, specialist visits, and sometimes biopsies. A complete model should include:

• Expected test volume by age band and eligibility rules
• Projected positive results and the downstream diagnostic workup cost per result
• Any savings assumptions tied to earlier-stage diagnosis, clearly labeled as assumptions
• Administrative costs for plan document changes and member communication

Self-Funded and Fully Insured Plans Move Differently

If your plan is fully insured, coverage of a multi-cancer early detection test will follow your carrier’s medical policy once FDA approval is final. You will have limited room to move ahead of the carrier.

If your plan is self-funded, you decide on your own timeline. Carrier and TPA medical policies will set a default, but you can choose to cover the test, exclude it, or offer it through a wellness or navigation program. Any change needs plan document and SPD updates, and your stop loss carrier should be informed. If you are weighing funding arrangements more broadly, our guide to self-funded vs. fully insured plans walks through the tradeoffs.

Coverage Options Beyond Yes or No

Self-funded plans are not limited to a simple cover or exclude choice. There is a middle ground worth considering once the FDA issues its decision:

• Cover under the medical plan with criteria. Limit eligibility by age, set a frequency cap, and require a physician order, mirroring whatever CMS adopts.
• Offer through a wellness or navigation program. This keeps the multi-cancer early detection test outside core plan design while you watch the evidence mature.
• Cover with cost sharing. Because the ACA preventive care mandate does not apply, you can apply a deductible or coinsurance to manage demand.
• Wait for more data. Deferring coverage until mortality evidence arrives is a defensible fiduciary position, as long as you document why.

Each option carries different plan document, stop loss, and communication implications. The right answer depends on your population, your budget, and how much evidence you want before you act.

Protect Existing Screenings in Member Communications

Member messaging carries real risk here. If employees read “one blood test for 50 cancers” as a substitute for their colonoscopy, your plan could see lower participation in screenings with proven benefit. Every communication should make three points clear:

• The multi-cancer early detection test does not replace mammograms, colonoscopies, or other recommended screenings.
• A negative result does not rule out cancer.
• A positive result means more testing, not a diagnosis.

Document the Decision as a Fiduciary

Whatever you decide about a multi-cancer early detection test, make the decision through a documented process. Record the evidence you reviewed, the cost model, the options you considered, and why you chose the path you did. That record protects the plan and shows your people that the decision was made in their best interest.

A Practical Checklist: 7 Essential Steps for Plan Sponsors

Use this list to prepare before the FDA issues its final decision on the first multi-cancer early detection test:

1. Confirm whether your plan is self-funded or fully insured, and who sets coverage policy for new screenings.
2. Ask your carrier or TPA how and when it will issue a medical policy on multi-cancer screening.
3. Pull your census to estimate how many members are aged 50 and older.
4. Build a cost model that includes follow-up care, not just the test price.
5. Review your stop loss contract for how new covered services are handled.
6. Draft member communication language that protects participation in existing screenings.
7. Set a decision date ahead of your 2028 renewal and document the process.

Questions to Ask Before You Cover a Multi-Cancer Early Detection Test

When a vendor, carrier, or employee raises the topic, these questions will help you separate strategy from sales:

• What does the final FDA label allow the test to claim, and what warnings does it carry?
• What is the expected number of positive results in our population, and what will each workup cost?
• How will our TPA adjudicate follow-up imaging and biopsies after a positive multi-cancer early detection test?
• Does our stop loss carrier treat the test and its follow-up care as covered expenses?
• How will we measure whether the benefit is working for our members over time?
• How will we keep members on track with the screenings that already have proven benefit?

If the answers are unclear, that is useful information too. A benefit you cannot measure or explain to your people is a benefit worth waiting on.

What to Watch Next

• The FDA decision. A final ruling on the premarket approval application is expected in the coming months.
• The approved label. Watch whether the FDA allows “early detection” language and what warnings it requires about false negatives and follow-up testing.
• The CMS coverage process. A National Coverage Determination will likely become the benchmark commercial carriers follow.
• Carrier medical policies. National carriers and major TPAs will each take a position once approval is final.
• Competing tests. Other multi-cancer tests are in development and will follow the regulatory path Galleri sets.

Frequently Asked Questions

Is the Galleri multi-cancer early detection test FDA approved?

Not yet. An FDA advisory panel voted in favor of approval on September 23, 2026, but the FDA makes the final decision and is expected to do so in the coming months.

Do employer health plans have to cover a multi-cancer early detection test?

No. Because the test has no USPSTF A or B grade, the ACA preventive care mandate does not require coverage without cost sharing. Fully insured plans will follow carrier policy, and self-funded plans can decide for themselves.

How much does the Galleri test cost?

The list price is $949. Most health plans do not cover it today, so members typically pay out of pocket.

Can a multi-cancer early detection test replace routine cancer screenings?

No. NCI and the FDA panel both stress that a multi-cancer early detection test should be used in addition to recommended screenings, never as a replacement.

When will Medicare cover multi-cancer screening?

Under the MCED Act, Medicare coverage can begin as early as 2028, once a test is FDA approved and CMS completes its coverage determination.

This article is provided for general informational purposes and does not constitute legal, tax, or medical advice. Information is current as of September 25, 2026, and may change as the FDA completes its review.